Comparing transplantation outcomes: haploidentical vs. unrelated donors 

 Comparing transplantation outcomes: haploidentical vs. unrelated donors 

2025.11.24
At the 50th Annual Meeting of the EBMT in Glasgow, Scotland, Raynier Devillier, MD, PhD, of the Paoli-Calmettes Institute in Marseille, France, offered a detailed comparison of transplantation outcomes for patients receiving grafts from haploidentical versus unrelated donors. Dr. Devillier highlighted new data from The French Society of Marrow Transplantation and Cellular Therapy (SFGM-TC) that indicates survival outcomes are comparable between the two donor types. This finding allows clinicians greater flexibility to select a donor based on the individual needs of the patient. 
Professor John E.J. Rasko AO: The Present and Future of Hemophilia Gene Therapy – From Long-Term Efficacy to Future Challenges 

Professor John E.J. Rasko AO: The Present and Future of Hemophilia Gene Therapy – From Long-Term Efficacy to Future Challenges 

2025.11.24
In recent years, breakthroughs in gene and cell therapy have brought revolutionary hope for the diagnosis and treatment of genetic diseases and malignant tumors. Recently, a six-year long-term follow-up study published in The New England Journal of Medicine confirmed the lasting efficacy and favorable safety of adeno-associated virus (AAV)-mediated Factor IX gene therapy for patients with hemophilia B. However, extending this therapy to a broader patient population still faces numerous challenges. Meanwhile, cell therapies, represented by CAR-T therapy, have shown immense potential in hematological malignancies and autoimmune diseases, with their technological development entering a new phase. From November 13-16, 2025, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) will be held in Hangzhou, Zhejiang. During the conference, Oncology Horizon - Hematology Express specifically invited Professor John E.J. Rasko AO from the Royal Prince Alfred Hospital, Australia, to systematically elaborate on the clinical progress, existing challenges, and future directions of these advanced therapies, with the aim of providing reference for clinical practice and research in this field. 
Microbiota Modulation: A New Pillar in aGVHD Treatment 

Microbiota Modulation: A New Pillar in aGVHD Treatment 

2025.11.24
Professor Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, Paris, discusses a paradigm shift in managing acute graft-versus-host disease (aGVHD).He highlights the critical role of gut microbiota dysbiosis in the pathogenesis of aGVHD following allogeneic hematopoietic stem cell transplantation and elaborates on the therapeutic potential of microbiota modulation. 
A New Era for AML Treatment: Integrating Novel Therapies and Global Collaboration 

A New Era for AML Treatment: Integrating Novel Therapies and Global Collaboration 

2025.11.24
Professor Norbert Claude Gorin, the first Chair of the Global Committee of the European Society for Blood and Marrow Transplantation (EBMT), discussed the evolution of transplantation strategies for Acute Myeloid Leukemia (AML) and the importance of international cooperation. In an interview with Hematology Frontier during the second 2025 CTI conference in Hangzhou, he highlighted how decades of progress have reshaped the treatment landscape. 
When the breeze rises over West Lake and wisdom sends ripples across the world, when the Qiantang tide surges and innovation breaks waves toward a new era— the 2025 International Cell and Immunotherapy Congress officially opens 

When the breeze rises over West Lake and wisdom sends ripples across the world, when the Qiantang tide surges and innovation breaks waves toward a new era— the 2025 International Cell and Immunotherapy Congress officially opens 

2025.11.21
On November 14, 2025, the Second International Cell and Immunotherapy Congress convened in Hangzhou. The meeting is co-chaired by He Huang from the First Affiliated Hospital of Zhejiang University School of Medicine and Mohamad Mohty, President of the International Academy for Clinical Hematology (IACH). Clinical experts, basic researchers, young scientists, and representatives from biopharmaceutical enterprises gathered from around the globe to engage in in-depth discussions on the latest advances in cell and immunotherapy. The congress not only showcased cutting-edge scientific achievements but also fostered meaningful interdisciplinary collaboration, illuminating key directions for future innovation in cell therapy, immunotherapy, and hematologic research. Oncology Frontier – Hematology Frontier Update has compiled highlights from the first day of the conference to share this academic event with colleagues and explore new frontiers in the field together.